190 related articles for article (PubMed ID: 33485947)
1. MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Sagar S; Leiphrakpam PD; Thomas D; McAndrews KL; Caffrey TC; Swanson BJ; Clausen H; Wandall HH; Hollingsworth MA; Radhakrishnan P
Cancer Lett; 2021 Apr; 503():91-102. PubMed ID: 33485947
[TBL] [Abstract][Full Text] [Related]
2. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
3. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
4. MUC4-promoted neural invasion is mediated by the axon guidance factor Netrin-1 in PDAC.
Wang L; Zhi X; Zhu Y; Zhang Q; Wang W; Li Z; Tang J; Wang J; Wei S; Li B; Zhou J; Jiang J; Yang L; Xu H; Xu Z
Oncotarget; 2015 Oct; 6(32):33805-22. PubMed ID: 26393880
[TBL] [Abstract][Full Text] [Related]
5. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Pan YR; Wu CE; Jung SM; Huang SC; Lin SH; Chou WC; Chang YC; Chen MH; Hung TH; Yu AL; Huang WK; Yeh CN
Int J Biol Sci; 2023; 19(9):2772-2786. PubMed ID: 37324940
[TBL] [Abstract][Full Text] [Related]
6. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism.
Zhang JJ; Zhu Y; Xie KL; Peng YP; Tao JQ; Tang J; Li Z; Xu ZK; Dai CC; Qian ZY; Jiang KR; Wu JL; Gao WT; Du Q; Miao Y
Mol Cancer; 2014 May; 13():130. PubMed ID: 24884523
[TBL] [Abstract][Full Text] [Related]
7. COSMC knockdown mediated aberrant O-glycosylation promotes oncogenic properties in pancreatic cancer.
Hofmann BT; Schlüter L; Lange P; Mercanoglu B; Ewald F; Fölster A; Picksak AS; Harder S; El Gammal AT; Grupp K; Güngör C; Drenckhan A; Schlüter H; Wagener C; Izbicki JR; Jücker M; Bockhorn M; Wolters-Eisfeld G
Mol Cancer; 2015 May; 14():109. PubMed ID: 26021314
[TBL] [Abstract][Full Text] [Related]
8. Development and
Urey C; Hilmersson KS; Andersson B; Ansari D; Andersson R
Anticancer Res; 2017 Nov; 37(11):6031-6039. PubMed ID: 29061782
[TBL] [Abstract][Full Text] [Related]
9. MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
Mimeault M; Johansson SL; Senapati S; Momi N; Chakraborty S; Batra SK
Cancer Lett; 2010 Sep; 295(1):69-84. PubMed ID: 20303649
[TBL] [Abstract][Full Text] [Related]
10. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.
Torres MP; Ponnusamy MP; Chakraborty S; Smith LM; Das S; Arafat HA; Batra SK
Mol Cancer Ther; 2010 May; 9(5):1419-31. PubMed ID: 20423995
[TBL] [Abstract][Full Text] [Related]
11. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
12. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
Bafna S; Kaur S; Momi N; Batra SK
Br J Cancer; 2009 Oct; 101(7):1155-61. PubMed ID: 19738614
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
15. The antagonistic regulation of human MUC4 and ErbB-2 genes by the Ets protein PEA3 in pancreatic cancer cells: implications for the proliferation/differentiation balance in the cells.
Fauquette V; Perrais M; Cerulis S; Jonckheere N; Ducourouble MP; Aubert JP; Pigny P; Van Seuningen I
Biochem J; 2005 Feb; 386(Pt 1):35-45. PubMed ID: 15461591
[TBL] [Abstract][Full Text] [Related]
16. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
17. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
[TBL] [Abstract][Full Text] [Related]
18. CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
Maity G; Ghosh A; Gupta V; Haque I; Sarkar S; Das A; Dhar K; Bhavanasi S; Gunewardena SS; Von Hoff DD; Mallik S; Kambhampati S; Banerjee SK; Banerjee S
Mol Cancer Ther; 2019 Apr; 18(4):788-800. PubMed ID: 30787177
[TBL] [Abstract][Full Text] [Related]
19. Truncated O-Glycan-Bearing MUC16 Enhances Pancreatic Cancer Cells Aggressiveness via α4β1 Integrin Complexes and FAK Signaling.
Rajesh C; Sagar S; Rathinavel AK; Chemparathy DT; Peng XL; Yeh JJ; Hollingsworth MA; Radhakrishnan P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628269
[TBL] [Abstract][Full Text] [Related]
20. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer.
Lahdaoui F; Delpu Y; Vincent A; Renaud F; Messager M; Duchêne B; Leteurtre E; Mariette C; Torrisani J; Jonckheere N; Van Seuningen I
Oncogene; 2015 Feb; 34(6):780-8. PubMed ID: 24608432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]